NBSE NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington's Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.

$4.92
As of 06/21/2021     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/15/2019
Outstanding shares:  32,716,827
Average volume:  248,052
Market cap:   $151,478,909
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    64132K102
ISIN:        US64132K1025
Sedol:      BJ9NDZ8

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   98.40
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%